Mortality in people taking selegiline: observational study.
OBJECTIVE
To evaluate mortality among patients with Parkinson's disease receiving different treatment.


METHODS
Cohort study based on computerised medical records.


METHODS
UK General Practice Research Database.


METHODS
12 621 patients aged between 35 and 90 years who had received a prescription for an antiparkinsonian drug, whether or not a diagnosis of Parkinson's disease had been recorded. Patients prescribed an antipsychotic drug before or at the same time as their first antiparkinsonian drug or before age 35 were excluded to avoid including drug-induced Parkinsonism.


METHODS
Death from any cause.


RESULTS
1720 deaths occurred during 14 000 person-years of observation. There was a non-significant 11% (95% confidence interval 0% to 23%) increase in the risk of death associated with taking selegiline either alone or in combination with levodopa. The death rate was higher among younger patients (aged under 80 years) and those with a recorded diagnosis of Parkinson's disease taking selegiline alone.


CONCLUSIONS
The results are compatible with a small excess mortality in people taking selegiline and suggest a larger excess in patients under 80 years of age and those with a confirmed diagnosis of Parkinson's disease taking selegiline without levodopa.
Health Promotion Research Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT. m.thorogood@lshtm.ac.uk
M
M
Thorogood
B
B
Armstrong
T
T
Nichols
J
J
Hollowell
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects*; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000401:mortality*; D012307:Risk Factors; D012642:Selegiline / Q000009:adverse effects*; D015996:Survival Rate; D006113:United Kingdom / Q000453:epidemiology
D000978:Antiparkinson Agents; D012642:Selegiline